Apyx Medical (NASDAQ:APYX) Trading 0.9% Higher – Here’s What Happened

Apyx Medical Corporation (NASDAQ:APYX)’s share price rose 0.9% during mid-day trading on Friday . The stock traded as high as $3.59 and last traded at $3.49. Approximately 26,658 shares changed hands during mid-day trading, a decline of 42% from the average daily volume of 46,115 shares. The stock had previously closed at $3.46.

Wall Street Analysts Forecast Growth

APYX has been the subject of several research reports. Wall Street Zen upgraded shares of Apyx Medical to a “hold” rating in a report on Saturday, November 22nd. Zacks Research upgraded shares of Apyx Medical to a “hold” rating in a research report on Wednesday, December 17th. Roth Capital initiated coverage on shares of Apyx Medical in a research note on Monday, December 15th. They set a “buy” rating and a $6.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a research note on Monday, December 29th. Finally, Citizens Jmp upgraded Apyx Medical from a “market perform” rating to an “outperform” rating and set a $8.00 price objective for the company in a report on Wednesday, November 12th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Apyx Medical currently has an average rating of “Moderate Buy” and an average target price of $7.00.

Apyx Medical Stock Performance

The company has a debt-to-equity ratio of 5.69, a quick ratio of 3.61 and a current ratio of 4.44. The stock’s 50-day simple moving average is $3.76 and its two-hundred day simple moving average is $2.82. The stock has a market cap of $133.46 million, a price-to-earnings ratio of -9.69 and a beta of 1.53.

Apyx Medical (NASDAQ:APYX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. Apyx Medical had a negative return on equity of 151.01% and a negative net margin of 30.35%.The company had revenue of $12.88 million during the quarter, compared to analyst estimates of $12.00 million. Analysts forecast that Apyx Medical Corporation will post -0.68 earnings per share for the current year.

Institutional Trading of Apyx Medical

Several institutional investors have recently bought and sold shares of APYX. Citadel Advisors LLC bought a new position in Apyx Medical in the third quarter valued at about $28,000. Fisher Asset Management LLC bought a new position in shares of Apyx Medical in the 2nd quarter valued at about $34,000. Kingsview Wealth Management LLC grew its position in shares of Apyx Medical by 9.4% during the 2nd quarter. Kingsview Wealth Management LLC now owns 191,597 shares of the company’s stock worth $431,000 after buying an additional 16,502 shares during the period. Caprock Group LLC bought a new stake in shares of Apyx Medical during the third quarter worth approximately $40,000. Finally, Osaic Holdings Inc. bought a new stake in shares of Apyx Medical during the second quarter worth approximately $50,000. Institutional investors and hedge funds own 55.33% of the company’s stock.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.